Panbela Therapeutics, Inc. (PBLA)
USD 0.26
(-3.7%)
USD 0.26
(-3.7%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 25.64 Million USD | -24.77% |
| 2022 | 34.09 Million USD | 240.59% |
| 2021 | 10.01 Million USD | 73.97% |
| 2020 | 5.75 Million USD | 33.13% |
| 2019 | 4.32 Million USD | 12.64% |
| 2018 | 3.83 Million USD | -36.22% |
| 2017 | 6.01 Million USD | 16.41% |
| 2016 | 5.16 Million USD | -5.07% |
| 2015 | 5.44 Million USD | 550.23% |
| 2014 | 837.24 Thousand USD | 37.33% |
| 2013 | 609.67 Thousand USD | 136.22% |
| 2012 | 258.09 Thousand USD | 1.73% |
| 2011 | 253.71 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.72 Million USD | -4.51% |
| 2024 Q2 | 8.1 Million USD | 20.47% |
| 2023 Q3 | 7.84 Million USD | 33.5% |
| 2023 FY | 25.64 Million USD | -24.77% |
| 2023 Q1 | 4.86 Million USD | -5.15% |
| 2023 Q2 | 5.87 Million USD | 20.93% |
| 2023 Q4 | 7.04 Million USD | -10.22% |
| 2022 Q2 | 21.28 Million USD | 431.62% |
| 2022 Q1 | 4 Million USD | 20.57% |
| 2022 FY | 34.09 Million USD | 240.59% |
| 2022 Q4 | 5.12 Million USD | 41.43% |
| 2022 Q3 | 3.62 Million USD | -82.98% |
| 2021 FY | 10.01 Million USD | 73.97% |
| 2021 Q2 | 2.22 Million USD | -0.98% |
| 2021 Q4 | 3.32 Million USD | 50.27% |
| 2021 Q3 | 2.21 Million USD | -0.72% |
| 2021 Q1 | 2.24 Million USD | 40.41% |
| 2020 Q2 | 1.1 Million USD | 3.56% |
| 2020 Q4 | 1.6 Million USD | -19.79% |
| 2020 Q3 | 1.99 Million USD | 80.8% |
| 2020 Q1 | 1.06 Million USD | -15.06% |
| 2020 FY | 5.75 Million USD | 33.13% |
| 2019 Q4 | 1.25 Million USD | -6.48% |
| 2019 Q3 | 1.34 Million USD | 23.35% |
| 2019 Q2 | 1.08 Million USD | 66.62% |
| 2019 Q1 | 653 Thousand USD | 2.83% |
| 2019 FY | 4.32 Million USD | 12.64% |
| 2018 Q1 | 1.22 Million USD | -32.12% |
| 2018 FY | 3.83 Million USD | -36.22% |
| 2018 Q4 | 635 Thousand USD | -28.49% |
| 2018 Q3 | 888 Thousand USD | -18.08% |
| 2018 Q2 | 1.08 Million USD | -11.73% |
| 2017 Q4 | 1.8 Million USD | 73.11% |
| 2017 Q1 | 1.99 Million USD | -5.63% |
| 2017 Q2 | 1.16 Million USD | -41.73% |
| 2017 Q3 | 1.04 Million USD | -10.07% |
| 2017 FY | 6.01 Million USD | 16.41% |
| 2016 Q4 | 2.11 Million USD | 86.17% |
| 2016 FY | 5.16 Million USD | -5.07% |
| 2016 Q2 | 949 Thousand USD | -2.67% |
| 2016 Q3 | 1.13 Million USD | 19.6% |
| 2016 Q1 | 975 Thousand USD | -20.73% |
| 2015 Q2 | 230.65 Thousand USD | 5.24% |
| 2015 FY | 5.44 Million USD | 550.23% |
| 2015 Q4 | 1.23 Million USD | 59.74% |
| 2015 Q3 | 770 Thousand USD | 233.84% |
| 2015 Q1 | 219.16 Thousand USD | -24.37% |
| 2014 Q3 | 237.24 Thousand USD | 15.6% |
| 2014 FY | 837.24 Thousand USD | 37.33% |
| 2014 Q2 | 205.22 Thousand USD | 95.52% |
| 2014 Q1 | 104.96 Thousand USD | -74.88% |
| 2014 Q4 | 289.8 Thousand USD | 22.15% |
| 2013 Q3 | 70.14 Thousand USD | 75.56% |
| 2013 Q2 | 39.95 Thousand USD | -47.27% |
| 2013 FY | 609.67 Thousand USD | 136.22% |
| 2013 Q4 | 417.8 Thousand USD | 495.61% |
| 2013 Q1 | 75.76 Thousand USD | 23.82% |
| 2012 FY | 258.09 Thousand USD | 1.73% |
| 2012 Q3 | 63.75 Thousand USD | -4.27% |
| 2012 Q4 | 61.19 Thousand USD | -4.01% |
| 2012 Q1 | 66.56 Thousand USD | 0.0% |
| 2012 Q2 | 66.59 Thousand USD | 0.05% |
| 2011 FY | 253.71 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -3778.669% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -176.726% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 14.49% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 61.805% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -61.882% |
| Better Therapeutics, Inc. | 38.26 Million USD | 32.97% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 36.968% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -106.952% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 24.22% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 25.486% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 76.355% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -2483.276% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 21.302% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 45.375% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -2011.406% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -28.625% |
| Molecular Templates, Inc. | 63.09 Million USD | 59.349% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -84.092% |
| NexImmune, Inc. | 28.16 Million USD | 8.948% |
| Orgenesis Inc. | 45.75 Million USD | 43.95% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -34833.802% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -58.851% |
| Scopus BioPharma Inc. | 11.71 Million USD | -118.927% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 93.645% |
| Statera Biopharma, Inc. | 28.82 Million USD | 11.039% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -35.491% |
| Trevena, Inc. | 38.41 Million USD | 33.234% |
| Vaxxinity, Inc. | 56.05 Million USD | 54.243% |
| Vaccinex, Inc. | 23.45 Million USD | -9.346% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -2349.622% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 49.407% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -252.554% |